SCHEMBL2056927

SCHEMBL2056927

COC(=O)C(NC(C)=O)C(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
TSHR P16473 1/20 0.46
GAA P10253 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.44
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
MTNR1A P48039 3/20 0.41
MTNR1B P49286 3/20 0.41
ESRRB O95718 1/20 0.41
HCRTR2 O43614 1/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
CA3 P07451 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28490874 0.88 ACACB (0.51) ALDH1A1
SCHEMBL28550392 0.87 L3MBTL1 (0.48) TSHRALDH1A1CYP3A4MTNR1AMTNR1B
SCHEMBL27763261 0.87 ALDH1A1 (0.41) KMT2ATSHRALDH1A1CYP3A4MTNR1A
SCHEMBL1968423 0.85 CA12 (0.55) KMT2AGAAALDH1A1MTNR1AMTNR1B
SCHEMBL1398751 0.85 TDP1 (0.47) KMT2AGAAALDH1A1CA12CA1
Iodide SCHEMBL5351689 0.84 CA12 (0.54) KMT2AGAAALDH1A1MTNR1AMTNR1B
Bromide SCHEMBL7614615 0.84 CA12 (0.54) KMT2AGAAALDH1A1MTNR1AMTNR1B
SCHEMBL11317047 0.84 L3MBTL1 (0.44) TSHRALDH1A1CYP3A4MTNR1AMTNR1B
SCHEMBL1398764 0.83 CA1 (0.50) ALDH1A1CA12CA1CA2CA9
SCHEMBL1398810 0.83 TSHR (0.41) KMT2ATSHRGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2771006-B1 PROCESS FOR MAKING BETA 3 ANGONISTS AND INTERMEDIATES MERCK SHARP & DOHME (US) 2016-05-25 EP disclosed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US disclosed
WO-2010038200-A1 OXAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-04-08 WO disclosed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR KMT2A 1736/4885TSHR 40/4885GAA 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.